We report on the state of the art of proteins recognized as potential targets for the development of leishmania treatments through the search of biologically active chemical species, either from experimental in vitro, in vivo, or in silico sources. We classify the gathered information, in several ways: vector taxonomy and geographical distribution, leishmania parasite taxonomic and geographical distribution and enzymatic function (oxidoreductases, transferases, hydrolases, lyases, isomerases, ligases and cytokines).
Introduction
Leishmaniasis is a tropical and subtropical group of zoonotic diseases, caused for different species of Leishmania genus.
1,2 It mainly affects mammalians and is transmitted through 
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Figure 3: Leishmania life cycle can be divided in five steps.
Step 1: Virulent metacyclic promastigotes are egested when a female sandfly carrier bites a possible host.
Step 2: Here there are two possible paths. Direct path: promastigotes are phagocytized by macrophage cells. Indirect path: promastigotes are phagocytized by neutrophil cells, subsequently, neutrophils are phagocytized by macrophage. At the end of step 2, promastigotes end up inside a macrophage phagolysosome.
Step 3: The promastigote parasite produces glutathione transferase, a protein that protects it from the acidic conditions of the phagolysosome, then initiating the replication process .
Step 4: Transformation of vector promastigote into amastigote takes place. Leishmania amastigotes are experts at exploiting host cell machinery to thrive. and is believed to be crucial for the survival of infectious Leishmania parasite.
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Transferases group (EC. 2)
Transferases catalyze reactions in which a chemical group is transferred from a electron/proton donor substrate to an electron/proton acceptor substrate. 34 These proteins catalyze key cellular processes in all kingdoms of life, such as, DNA repair, RNA editing, and activation of metabolites used in catabolic pathways. 52 Adenine phosphoribosyltransferase (APRT) (PDB ID: 1QB7 and 1MZV) belongs to the phosphoribosyltransferase family type I (PRTs) and is involved in the purine-salvaging process, catalyzing adenines to adenosine-5-monophosphate Figure 4 : Leishmania protein classification. Oxidoreductases (orange), transferases (blue), hydrolases (red), lyases (violet), isomerases (green), ligases (dark blue) and cytokines (yellow). The chart at the bottom right of the figure shows the number of proteins found for each species. T. cruzi and T. brucei do not belong at the Leishmania protein group, but they have been used in some studies as homologous proteins.
39,51
such as gene translation. 78, 79 The three enzyme is Asparagine synthetase A (ASNA) (PDB ID: 4LNS), which is an ammonium and glutamine dependent enzyme. In experimental (in vivo and in vitro) studies, this protein-deletion-gene caused parasite growth delay, therefore is recognized as a possible target.
51

Cytokines group
The Migration Inhibitory Factor (MIF) from L. major (PDB ID: 3B64) was classified as possible enzymatic target. This cytokine is an ortholog of human MIF, also known as Lm1740MIF. 3B64 interacts with MIF receptors, HLA class II histocompatibility antigen gamma chain (also called invariant chain or CD74) and exhibits an antiapoptotic activity that may facilitate the intracellular persistence of Leishmania into macrophages.
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Leishmaniasis drugs
Pentavalent antimonials (Sb(V)) were firsts leishmaniasis drugs for along time, however, development of Leishmania resistance made it drug inefficient. New drug and treatment investigations have been development. 2 Currently, being developed much effective drugs, but it generates secondary effects as high toxicity, also, these treatments and drugs are expensive and generates resistance for Leishmania parasites.
81,82
Leishmaniasis disease is a Neglected Tropical Disease (NTD), therefore, it does not have necessaries economic funds and strict epidemiological controls from governmental organizations, made difficult drugs and treatments development.
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Standard drugs
Currently, leishmaniasis is treated using the following types of chemical substances: antimonials (Sb(V)), amphotericin B, Pentamidine, Miltefosine (hexadecylphosphocholine), paromomycin (aminosidine), sitamaquine and pamidronate (see Fig. 5 ). 17, 84 These drugs are used for treats three main leishmaniasis forms: cutaneous leishmaniasis (CL), mucocu-antileishmania compounds, introduced in the 40s decade. 2, 84 They are available as meglumine antimoniate (Glucantime) and sodium stibogluconate (Pentostam), and these are standard first line drugs for treatment, but emergence of resistance has limited their use.
16,82
Antimonials are used for VL treatment, but, different studies found that L. donovani and L. braziliensis were more sensitive to sodium stibogluconate than L. major, Leishmania tropica and L. mexicana. 2,17 Amphotericin B is a macrolide antibiotic isolated from Streptomyces nodosus in 1956 and widely used since the 80s as amphotericin B deoxycholate.
2,84
It selectively inhibits the membrane synthesis of the parasite and causes holes in the membrane, leading to parasite death. 84 It is used as a second-line treatment, and is present in Pentamidine is widely recognised, its antileishmanial activity is on Leishmania parasite polyamines biosynthesis and mitochondrial membrane. They are considered second-line treatment drugs for VL, because its toxicity (myalgia, nausea, headache, hypoglycemia, irreversible insulin dependent diabetes mellitus and death), declining its efficacy. Also, its hig2 monetary costs renders them prohibitive. 84 India and East Africa used paromomycin as a cheap alternative treatment, despite its toxicity. 2 Paromomycin remained neglected until the 80s, when topical formulations for VL were developed. 84 One World Health, the Bill and Melinda Gates Foundation, Gland Pharma Limited, IDA Solutions and WHO/TDR partnered to develop Paromomycin as a public health tool to be sold on a not-for-profit basis, at a very low price. 84 Miltefosine, initially developed as an anticancer drug, currently is the first Figure 5 : Drugs used against leishmaniasis can be divided in two main groups: standard drugs and alternative drugs (metabolites). Graphics show molecular structures of drug active compounds. Structures were obtained from ChemSpider (http://www.chemspider.com/).
